These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 15358977

  • 21. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
    Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN.
    CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
    [Abstract] [Full Text] [Related]

  • 22. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ.
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [Abstract] [Full Text] [Related]

  • 23. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.
    Tyson PJ, Laws KR, Flowers KA, Tyson A, Mortimer AM.
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450
    [Abstract] [Full Text] [Related]

  • 24. The role of serotonin in antipsychotic drug action.
    Meltzer HY.
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):106S-115S. PubMed ID: 10432496
    [Abstract] [Full Text] [Related]

  • 25. Pathophysiology of antipsychotic drug-induced movement disorders.
    Casey DE.
    J Clin Psychiatry; 2004 Aug; 65 Suppl 9():25-8. PubMed ID: 15189109
    [Abstract] [Full Text] [Related]

  • 26. Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus.
    Fiorino F, Severino B, De Angelis F, Perissutti E, Magli E, Frecentese F, Esposito A, Massarelli P, Nencini C, Viti B, Santagada V, Caliendo G.
    Pharmazie; 2009 Sep; 64(9):555-64. PubMed ID: 19827295
    [Abstract] [Full Text] [Related]

  • 27. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S, Duncan GE, Marx CE, Lieberman JA.
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [Abstract] [Full Text] [Related]

  • 28. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
    Depoortère R, Barret-Grévoz C, Bardin L, Newman-Tancredi A.
    Eur J Pharmacol; 2008 Nov 12; 597(1-3):34-8. PubMed ID: 18773888
    [Abstract] [Full Text] [Related]

  • 29. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T, Nagao N, Nakahara T.
    Prog Brain Res; 2008 Nov 12; 172():199-212. PubMed ID: 18772034
    [Abstract] [Full Text] [Related]

  • 30. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
    Chłoń-Rzepa G, Zagórska A, Bucki A, Kołaczkowski M, Pawłowski M, Satała G, Bojarski AJ, Partyka A, Wesołowska A, Pękala E, Słoczyńska K.
    Arch Pharm (Weinheim); 2015 Apr 12; 348(4):242-53. PubMed ID: 25773907
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
    Kapur S.
    Mol Psychiatry; 1998 Mar 12; 3(2):135-40. PubMed ID: 9577837
    [Abstract] [Full Text] [Related]

  • 34. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
    Rauser L, Savage JE, Meltzer HY, Roth BL.
    J Pharmacol Exp Ther; 2001 Oct 12; 299(1):83-9. PubMed ID: 11561066
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
    Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR.
    J Pharmacol Exp Ther; 2001 Oct 12; 299(1):268-76. PubMed ID: 11561089
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S, Soubrouillard C, Blin O.
    Encephale; 1997 Apr 12; 23 Spec No 2():10-6. PubMed ID: 9273300
    [Abstract] [Full Text] [Related]

  • 39. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
    Bruins Slot LA, Bardin L, Auclair AL, Depoortere R, Newman-Tancredi A.
    Behav Pharmacol; 2008 Mar 12; 19(2):145-52. PubMed ID: 18332679
    [Abstract] [Full Text] [Related]

  • 40. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.
    Pharmacol Biochem Behav; 2005 Oct 12; 82(2):361-72. PubMed ID: 16216322
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.